Education Blog for Healthcare Professionals

Posts Tagged ‘Aspirin’

Aspirin Decreases Recurrent DVT and PE

| Aspirin, Plavix, Aggrenox, Tiklid, Persantine, Therapy, Uncategorized | Comments Off on Aspirin Decreases Recurrent DVT and PE

Stephan Moll, MD writes… Aspirin is beneficial in preventing recurrent venous thromboembolism (VTE) in patients who have had a previous episode of unprovoked VTE and who have been treated with anticoagulant therapy, a publication in the journal Circulation re-confirms this week: Aspirin reduces the risk of recurrent VTE by more than a third without significantly increasing the risk of bleeding [ref 1].  This publication does not report results of a new study, but is rather a further analysis of the previously published WARFASA and ASPIRE aspirin trials [ref 2,3]. Read the rest of this entry »

Does Aspirin Prevent Recurrent DVT and PE? – ASPIRE Trial

| Therapy, Uncategorized, Warfarin (Coumadin) | Comments Off on Does Aspirin Prevent Recurrent DVT and PE? – ASPIRE Trial

Stephan Moll, MD writes… Well, it is not clear whether it does.  A clinically relevant study (ASPIRE study) was published this week (Nov 22nd,2012) in the N Engl J Med  [ref 1].  In patients who had a previous unprovoked (= idiopathic) DVT or PE and who had completed standard length (often considered to be 3-6 months) of warfarin therapy, aspirin did not prevent recurrent VTE.  However aspirin was effective in preventing further thrombotic event (a conglomerate of arterial and venous events).  Aspirin did not lead to an increase in risk of major bleeding. The findings are discrepant to the earlier WARFASA study, published in May 2012 in the N Engl J Med, which showed that Aspirin had efficacy in preventing recurrent VTE [ref 2].  The ASPIRE authors have also included a revealing,  meta-analysis of this week’s study plus the previous WARFASA study  [ref 2].

Read the rest of this entry »

Aspirin Prevents Recurrent DVT and PE – WARFASA Study

| Anticoagulants, Aspirin, Plavix, Aggrenox, Tiklid, Persantine, Therapy, Uncategorized | Comments Off on Aspirin Prevents Recurrent DVT and PE – WARFASA Study

Stephan Moll, MD writes… A clinically very relevant study (WARFASA) published today (May 24, 2012) in the New England Journal of Medicine [ref 1] shows that aspirin, 100 mg per day, reduces the risk of recurrent venous thromboembolism (VTE) in patients with unprovoked (= idiopathic) VTE, who have completed 6 to 18 months of anticoagulant therapy, without an apparent increase in risk of major bleeding Read the rest of this entry »